The vaccine developed by Pfizer in collaboration with German biotech company BioNTech is more than 90 percent effective against coronavirus, the drug manufacturing company claimed on Monday after its early analysis.

Though not much details have been revealed but it said that an independent panel of experts analysed the vaccine’s progress against the disease that had left more than 1.2 million people dead in less than one year.

The company said that no serious side effects were witnessed during the clinical trials.

Pfizer may ask the Food and Drug Administration for emergency authorization of the vaccine in the end of November the following year.

Kathrin Jansen, head of vaccine research and development at Pfizer, said it was historical as something like that never happened before. “Hearing that at the interim analysis we are over 90 percent effective — it was almost stunning to hear,” she said.

Also Read: Coronavirus vaccine enters third phase of clinical trials in Pakistan